PA Consulting, the international management, systems and technology consultancy based in the UK, has launched a new partnering initiative designed to accelerate time to market for new medicines.

The distributed scientific services (DS) concept is built around a new strategic partnership model that enables pharmaceutical companies to regain lost productivity in research and development, PA said.

The model draws on the benefits that different but complementary scientific organisations can bring to a partnership, while acknowledging that these organisations have varying cultures, needs and aspirations, the consultants explained.

“These complex, cross-organisational relationships need to be well thought out and managed, but [to] deliver value to our clients through reducing fixed costs and increasing speed to market,” commented Dr David Pardoe, who is heading up the DS initiative for PA Consulting. PA’s research and experience to date suggest that companies could achieve reductions in time to market of up to 20%.

The DS model also taps into PA’s established experience in building “agile” virtual organisations and outsourced services in other sectors, the consultants noted. It uses a number of existing PA technologies, such as ProcServe, an e-market place solution already employed in the UK government and the National Health Service.

“Uniquely, PA’s DS approach brings together the core business tools, process and sector knowledge needed to really address the issues and build strong and fruitful pharmaceutical pipelines,” Pardoe added.